Brought to you by 
CBT raises $9.75mm through Series A round
01 Sep 2016
Executive Summary
Immuno-oncology start-up CBT Pharmaceuticals Inc. raised $9.75mm through its Series A round led by OrbiMed Asia. The round brings CBT's total funding since its formation earlier this year to $14.75mm. (Crown Bioscience International Inc., CBT's parent, seeded the company with $5mm.)
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CBT raises $9.75mm through Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice